Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.91 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.91 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.91 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.91 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.91 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.91 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.91 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.91 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.91 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.91 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.91 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | CA7 | P43166 | 1/20 | 0.70 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Psammaplin A SCHEMBL29367050 | 1.00 | HDAC1 (0.91) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| Psammaplin A SCHEMBL12521616 | 1.00 | HDAC1 (0.91) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL4260599 | 0.95 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL30015295 | 0.94 | HDAC1 (0.83) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| Bisaprasin SCHEMBL2230766 | 0.92 | HDAC1 (0.78) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| Bisaprasin SCHEMBL12522054 | 0.92 | HDAC1 (0.78) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL13333433 | 0.90 | HDAC1 (0.80) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL17444829 | 0.90 | HDAC1 (0.84) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL17444828 | 0.90 | HDAC1 (0.84) | HDAC1HDAC6HDAC3HDAC2HDAC7 | |
| SCHEMBL15549016 | 0.89 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739291-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| EP-4739293-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| WO-2026041906-A1 | SEMI-SOLID PHARMACEUTICAL COMPOSITION MICRO-DISPENSER | Azura Ophthalmics Ltd. (IL) | 2026-02-26 | — | — | WO | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| CN-115925675-B | PSAMMAPLIN A derivatives, and preparation method and application thereof | 中国海洋大学 | 2025-04-01 | — | — | CN | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025012701-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012700-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| EP-4476217-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| CN-118660884-A | Crystal form of CFT7455 and method for producing same | C4医药公司 | 2024-09-17 | — | — | CN | claimed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | claimed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | claimed |
| EP-2040731-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | Merrion Research III Limited (IE) | 2009-04-01 | — | — | EP | claimed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | claimed |
| WO-2008036374-A2 | ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS | MEDISTEM LABORATORIES, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2007149548-A2 | TREATMENT OF ERECTILE DYSFUNCTION BY STEM CELL THERAPY | MEDISTEM LABORATORIES, INC. (US) | 2007-12-27 | — | — | WO | claimed |
| WO-2007146234-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | MERRION RESEARCH II LIMITED (IE) | 2007-12-21 | — | — | WO | claimed |
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | MERRION RESEARCH II LIMITED (IE) | 2007-12-20 | — | — | US | claimed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | CEL, SLC10A2, FABP2 | HDAC1 47/4885HDAC6 66/4885HDAC3 101/4885 |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | HDAC1 209/4885HDAC6 916/4885HDAC3 283/4885 |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | HDAC1 134/4885HDAC6 1413/4885HDAC3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.